TISIDB

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Nucleus matrix Nucleus speckle Nucleus, PML body Cytoplasm Note=Colocalizes with PRPF40A in the nuclear matrix (PubMed:16391387). Nuclear at steady state but shuttles between the nucleus and cytoplasm (PubMed:10748171). The shuttling property has been questioned (PubMed:11034899). Colocalizes with EBNA-LP in PML bodies (PubMed:11884601).
Domain	PF04988 A-kinase anchoring protein 95 (AKAP95)
Function	Could play a role in constitutive transport element (CTE)-mediated gene expression by association with DHX9. Increases CTE-dependent nuclear unspliced mRNA export (PubMed:10748171, PubMed:11402034). Proposed to target PRKACA to the nucleus but does not seem to be implicated in the binding of regulatory subunit II of PKA (PubMed:10761695, PubMed:11884601). May be involved in nuclear envelope breakdown and chromatin condensation. May be involved in anchoring nuclear membranes to chromatin in interphase and in releasing membranes from chromating at mitosis (PubMed:11034899). May regulate the initiation phase of DNA replication when associated with TMPO isoform Beta (PubMed:12538639). Required for cell cycle G2/M transition and histone deacetylation during mitosis. In mitotic cells recruits HDAC3 to the vicinity of chromatin leading to deacetylation and subsequent phosphorylation at 'Ser-10' of histone H3; in this function seems to act redundantly with AKAP8 (PubMed:16980585). May be involved in regulation of pre-mRNA splicing (PubMed:17594903). ; FUNCTION: (Microbial infection) In case of EBV infection, may target PRKACA to EBNA-LP-containing nuclear sites to modulate transcription from specific promoters. ; FUNCTION: (Microbial infection) Can synergize with DHX9 to activate the CTE-mediated gene expression of type D retroviruses. ; FUNCTION: (Microbial infection) In case of HIV-1 infection, involved in the DHX9-promoted annealing of host tRNA(Lys3) to viral genomic RNA as a primer in reverse transcription; in vitro negatively regulates DHX9 annealing activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0000070 mitotic sister chromatid segregation GO:0000819 sister chromatid segregation GO:0006323 DNA packaging GO:0006397 mRNA processing GO:0006403 RNA localization GO:0006405 RNA export from nucleus GO:0006406 mRNA export from nucleus GO:0006476 protein deacetylation GO:0006913 nucleocytoplasmic transport GO:0006997 nucleus organization GO:0006998 nuclear envelope organization GO:0007059 chromosome segregation GO:0007067 mitotic nuclear division GO:0007076 mitotic chromosome condensation GO:0008380 RNA splicing GO:0010793 regulation of mRNA export from nucleus GO:0015931 nucleobase-containing compound transport GO:0016570 histone modification GO:0016572 histone phosphorylation GO:0016575 histone deacetylation GO:0030261 chromosome condensation GO:0030397 membrane disassembly GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031063 regulation of histone deacetylation GO:0031065 positive regulation of histone deacetylation GO:0032239 regulation of nucleobase-containing compound transport GO:0032386 regulation of intracellular transport GO:0033127 regulation of histone phosphorylation GO:0035601 protein deacylation GO:0044770 cell cycle phase transition GO:0044839 cell cycle G2/M phase transition GO:0046822 regulation of nucleocytoplasmic transport GO:0046831 regulation of RNA export from nucleus GO:0050657 nucleic acid transport GO:0050658 RNA transport GO:0051028 mRNA transport GO:0051081 nuclear envelope disassembly GO:0051168 nuclear export GO:0051169 nuclear transport GO:0051236 establishment of RNA localization GO:0071103 DNA conformation change GO:0071166 ribonucleoprotein complex localization GO:0071426 ribonucleoprotein complex export from nucleus GO:0071427 mRNA-containing ribonucleoprotein complex export from nucleus GO:0090311 regulation of protein deacetylation GO:0090312 positive regulation of protein deacetylation GO:0098732 macromolecule deacylation GO:0098813 nuclear chromosome segregation GO:1902275 regulation of chromatin organization GO:1905269 positive regulation of chromatin organization GO:2000197 regulation of ribonucleoprotein complex localization
Molecular Function	GO:0005521 lamin binding GO:0017151 DEAD/H-box RNA helicase binding GO:0042826 histone deacetylase binding
Cellular Component	GO:0000785 chromatin GO:0016363 nuclear matrix GO:0016604 nuclear body GO:0016605 PML body GO:0016607 nuclear speck GO:0034399 nuclear periphery

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between AKAP8L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of AKAP8L in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 3	Resistant to T-cell proliferation

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of AKAP8L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.415	0.0439
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.522	0.806
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.337	0.827
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.258	0.339
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.386	0.871
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.098	0.975
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.099	0.767
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.167	0.91
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.037	0.982
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.295	0.872
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.176	0.643
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.021	0.707

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of AKAP8L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AKAP8L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AKAP8L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AKAP8L. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AKAP8L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of AKAP8L expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between AKAP8L and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	AKAP8L
Name	A kinase (PRKA) anchor protein 8-like
Aliases	NAKAP95; HAP95; neighbor of A kinase anchoring protein 95; HA95; NAKAP; AKAP8-like protein; helicase A-bindi ......
Chromosomal Location	19p13.12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting AKAP8L collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse AKAP8L